Metacrine Competitors

Delisted . USA . 
Stock . Metacrine
MTCRDelisted Stock  USD 0.49  0.00  0.00%   
Metacrine competes with Protara Therapeutics, CytomX Therapeutics, Assembly Biosciences, Instil Bio, and Nuvation Bio; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Metacrine competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Metacrine to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Metacrine competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Metacrine's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.490.490.49
Details
Intrinsic
Valuation
LowRealHigh
0.400.400.54
Details
Naive
Forecast
LowNextHigh
0.520.520.52
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.480.490.50
Details

Metacrine Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Metacrine and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Metacrine and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Metacrine does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
VCNX
+ 0.83
NUVB
TARA
+ 0.59
MGTA
CTMX
+ 0.57
NLTX
VCNX
+ 0.54
TCON
VCNX
+ 0.54
NLTX
STSA
+ 0.51
TARA
  
High negative correlations   
CTMX
- 0.74
TARA
TIL
- 0.69
MGTA
CTMX
- 0.63
STSA
NLTX
- 0.58
STSA
TIL
- 0.53
STSA
VCNX
- 0.52
STSA

Risk-Adjusted Indicators

There is a big difference between Metacrine Stock performing well and Metacrine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Metacrine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MGTA  2.62  0.19  0.00 (0.19) 3.40 
(3.33)
 5.88 
(4.29)
 16.99 
TARA  3.03  0.23  0.04  7.52  2.96 
(3.96)
 7.26 
(4.98)
 19.48 
TCON  6.84 (1.89) 0.00 (4.58) 0.00 
 0.00 
 19.59 
(17.77)
 52.05 
STSA  3.39  0.58  0.09 (0.79) 3.54 
(4.82)
 5.71 
(7.79)
 70.12 
NLTX  2.25 (0.22) 0.00 (0.55) 0.00 
 0.00 
 4.05 
(3.53)
 27.84 
CTMX  2.58 (0.53) 0.00 (0.35) 0.00 
 0.00 
 5.00 
(5.22)
 20.61 
ASMB  2.91  0.09  0.00  0.31  4.46 
(2.82)
 8.49 
(5.34)
 24.80 
TIL  9.42  1.47  0.25  0.40  6.84 
(12.97)
 20.63 
(10.89)
 105.83 
NUVB  3.76 (0.36) 0.00  0.03  4.59 
(4.00)
 9.48 
(8.36)
 21.30 
VCNX  6.00 (0.21) 0.00 (0.22) 0.00 
 0.00 
 11.11 
(14.00)
 54.95 
All Fundamental Data

Metacrine Competitive Analysis

The better you understand Metacrine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Metacrine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Metacrine's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MTCR MGTA TARA TCON STSA NLTX CTMX ASMB TIL NUVB
 0.00 
 0.49 
Metacrine
 3.80 
 0.82 
Magenta
 4.37 
 2.39 
Protara
 52.38 
 1.60 
TRACON
 0.90 
 1.10 
Satsuma
 1.43 
 0.69 
Neoleukin
 2.30 
 0.89 
CytomX
 2.17 
 15.04 
Assembly
 5.61 
 26.15 
Instil
 3.70 
 2.80 
Nuvation
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Somewhat reliable
Very steady
Very steady
Very steady
Dangerous
Relatively risky
Unstable
Very risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Average
Dangerous
Dangerous
Dangerous
Above Average
Low
Average
About Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Buy
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Sell
Not Rated
Not Rated
Not Rated
Strong Sell
Strong Sell
Hold
Strong Sell
Current Ratio
22.29
10.22
28.94
1.17
9.18
12.78
2.05
8.31
8.51
33.58
Net Asset
79.99 M
146.65 M
78.95 M
10.11 M
54.94 M
115.95 M
201.79 M
137.47 M
325.63 M
621.48 M
Profit Margin
N/A
N/A
N/A
0.14
N/A
N/A
0.11
-2.12
N/A
N/A
EBITDA
(60.71 M)
(78.98 M)
(43.27 M)
(6.88 M)
(58.31 M)
(56.48 M)
(4.31 M)
(64.2 M)
(146.12 M)
(99.6 M)
Current Valuation
(23.98 M)
(32.66 M)
(29.52 M)
(2.64 M)
(35.53 M)
(35.02 M)
(37.34 M)
2.09 M
135.64 M
404.44 M
Price To Book
0.4
0.54
0.58
11.83
0.42
0.44
5.04
3.68
0.97
1.81
Operating Margin
N/A
N/A
N/A
-32.12
N/A
N/A
0.12
-1.43
N/A
-66.16
Retained Earnings
N/A
(402.03 M)
(200.38 M)
(240.5 M)
(211.79 M)
(451.06 M)
(723.45 M)
(785.75 M)
(580.98 M)
(342.8 M)
Current Asset
N/A
33.34 M
N/A
53.31 M
N/A
289 K
189.75 M
68.37 M
N/A
N/A
Beta
-0.73
2.12
1.79
1.24
0.1
1.1
1.06
0.59
1.74
1.36
Number Of Employees
10
67
26
17
25
7
120
65
49
203
Shares Outstanding
42.57 M
60.66 M
20.63 M
2.68 M
33.15 M
2.35 M
78.26 M
6.36 M
6.53 M
335.57 M
Cash Flow From Operations
(47.16 M)
(67.09 M)
(37.56 M)
3.68 M
(51.52 M)
(45.61 M)
(56.03 M)
22.74 M
(82.03 M)
(68 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
13.3 M
29.96 M
5.47 M
968 K
205 K
12.07 M
13.97 M
2.34 M
86.05 M
4.01 M
Return On Equity
-0.91
-0.65
-0.46
-12.77
-1.04
-0.38
-54.75
-1.02
-0.49
-0.96
Z Score
0.6
-3.88
N/A
N/A
99.83
-5.73
N/A
N/A
N/A
N/A
Return On Asset
-0.37
-0.29
-0.28
-0.2
-0.5
-0.19
0.0233
-0.35
-0.12
-0.14
Number Of Shares Shorted
87.42 K
383.03 K
2.74 M
166.13 K
130.12 K
26.4 K
5.67 M
7.95 K
376 K
11.32 M
Book Value Per Share
0.87
1.24
6.01
-0.66
1.14
34.18
-0.3
7.5
34.72
1.5
Current Liabilities
N/A
3.39 M
N/A
14.18 M
N/A
1.02 M
15.74 M
3.4 M
N/A
N/A
Total Asset
79.99 M
146.65 M
78.95 M
10.11 M
54.94 M
115.95 M
201.79 M
137.47 M
325.63 M
621.48 M
Debt To Equity
0.33
0.25
0.046
0.35
0.002
0.11
0.67
0.041
0.12
0.006
Short Ratio
0.21
1.38
14.46
0.95
0.05
1.7
9.58
0.41
2.29
7.28
Target Price
0.5
1.0
29.5
30.5
2.0
1.5
5.29
35.5
100.33
6.5
Shares Owned By Institutions
35.96
62.63
51.1
11.42
57.9
45.58
65.31
18.79
80.7
56.3
Market Capitalization
20.94 M
45.14 M
49.31 M
3.83 M
36.8 M
8.2 M
69.65 M
95.6 M
170.65 M
942.39 M
Price To Earning
N/A
-1.63
N/A
-1.51
22.12
-4.6
-11.41
-10.58
18.31
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
4.5
-0.03
-1.8
N/A
N/A
N/A
Price To Sales
N/A
N/A
N/A
0.45
N/A
N/A
0.55
4.45
55329.79
420.32
Net Income
(62.21 M)
(76.46 M)
(40.42 M)
(3.59 M)
(70.06 M)
(57.56 M)
(569 K)
(61.23 M)
(156.09 M)
(75.8 M)
Earnings Per Share
-1.93
-1.11
-2.64
106.4
-1.99
-12.28
0.16
-6.89
-11.56
-2.18
Shares Owned By Insiders
12.29
2.23
6.12
2.2
10.43
16.46
1.0
31.62
12.86
26.85
Revenue
N/A
N/A
N/A
12.04 M
N/A
N/A
101.21 M
7.16 M
N/A
N/A
Working Capital
N/A
101.05 M
62.56 M
(1.09 M)
46.69 M
88.07 M
27.02 M
94.56 M
150.2 M
602.46 M
Cash And Equivalents
55.53 M
128.28 M
98.46 M
13.58 M
68.06 M
116.46 M
194.29 M
116.69 M
354.61 M
703.8 M
Cash Per Share
1.3
2.13
8.74
0.63
2.15
2.73
2.94
2.41
2.73
3.22
Gross Profit
(45.47 M)
N/A
N/A
(13.89 M)
N/A
N/A
53.16 M
(63.9 M)
138 K
N/A
Day Typical Price
0.48
0.81
2.38
1.39
1.08
0.69
0.88
14.9
25.67
2.76
Accumulation Distribution
0.17
0.0482
0.0571
0.5
0.11
0.0563
0.0444
0.0493
0.1
0.0534
Market Facilitation Index
0.09
0.04
0.14
0.86
0.13
0.04
0.04
0.75
2.68
0.15
Daily Balance Of Power
N/A
0.75
0.7143
0.6395
(0.08)
(0.25)
0.5
0.4267
0.5187
0.6667
Period Momentum Indicator
N/A
0.03
0.1
0.55
(0.01)
(0.01)
0.02
0.32
1.39
0.1
Rate Of Daily Change
1.0
1.04
1.04
1.52
0.99
0.99
1.02
1.02
1.06
1.04
Day Median Price
0.48
0.81
2.38
1.28
1.08
0.69
0.88
14.83
25.43
2.74
Price Action Indicator
0.015
0.025
0.06
0.6
0.02
(0.01)
0.02
0.37
1.41
0.11
Relative Strength Index
81.47
42.18
89.01
7.51
60.84
49.78
8.69
46.79
11.13
19.01
Coefficient Of Variation
923.82
2966.12
1572.8
(610.48)
1667.7
(2,179)
(904.17)
2742.42
758.05
4182.25
Mean Deviation
2.76
2.62
3.03
6.84
3.39
2.25
2.58
2.91
9.42
3.76
Jensen Alpha
0.6235
0.1883
0.2344
(1.89)
0.5807
(0.22)
(0.53)
0.0862
1.47
(0.36)
Total Risk Alpha
(0.21)
(0.47)
(0.38)
(3.61)
(0.85)
(0.76)
(0.93)
(0.51)
(0.42)
(0.66)
Sortino Ratio
0.084
(0)
0.0365
N/A
0.093
N/A
N/A
0.0047
0.2539
(0)
Downside Variance
13.71
17.78
10.37
N/A
16.97
N/A
N/A
20.74
60.79
22.53
Standard Deviation
4.08
3.69
3.9
11.21
8.57
3.7
3.45
4.17
16.0
4.88
Kurtosis
3.94
3.46
0.7304
5.52
46.63
13.95
1.91
3.52
11.78
0.1535
Potential Upside
9.09
5.88
7.26
19.59
5.71
4.05
5.0
8.49
20.63
9.48
Treynor Ratio
(0.27)
(0.19)
7.52
(4.58)
(0.79)
(0.55)
(0.35)
0.3073
0.4016
0.0274
Maximum Drawdown
21.01
16.99
19.48
52.05
70.12
27.84
20.61
24.8
105.83
21.3
Variance
16.67
13.63
15.25
125.56
73.46
13.69
11.88
17.38
255.9
23.84
Market Risk Adjusted Performance
(0.26)
(0.18)
7.53
(4.57)
(0.78)
(0.54)
(0.34)
0.3173
0.4116
0.0374
Risk Adjusted Performance
0.0911
0.0338
0.0568
(0.12)
0.0551
(0.03)
(0.08)
0.0361
0.1107
0.0268
Skewness
1.41
(0.42)
0.7672
(0.27)
6.24
(2.77)
0.6992
(0.55)
3.03
0.2319
Semi Deviation
2.4
3.4
2.96
N/A
3.54
N/A
N/A
4.46
6.84
4.59
Information Ratio
0.0762
(0)
0.0301
(0.18)
0.0447
(0.08)
(0.15)
0.0051
0.1237
(0)
Value At Risk
(4.44)
(4.29)
(4.98)
(17.77)
(7.79)
(3.53)
(5.22)
(5.34)
(10.89)
(8.36)
Expected Short fall
(5.26)
(3.33)
(3.96)
N/A
(4.82)
N/A
N/A
(2.82)
(12.97)
(4.00)
Downside Deviation
3.7
4.22
3.22
N/A
4.12
N/A
N/A
4.55
7.8
4.75
Semi Variance
5.78
11.57
8.75
N/A
12.53
N/A
N/A
19.87
46.81
21.05

Metacrine Competition Performance Charts

Five steps to successful analysis of Metacrine Competition

Metacrine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Metacrine in relation to its competition. Metacrine's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Metacrine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Metacrine's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Metacrine, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Metacrine position

In addition to having Metacrine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Medical Equipment Thematic Idea Now

Medical Equipment
Medical Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Consideration for investing in Metacrine Stock

If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY